Sugi Predict

Sugi Predict / Compounds / SCHEMBL2233648

SCHEMBL2233648

SCHEMBL2233648

CC(C)(C)OC(=O)NCCCCI

nearest known ligand 0.68

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 1/20 0.68
▸ MEN1 O00255 1/20 0.59
▸ GAA P10253 1/20 0.59
▸ KMT2A Q03164 1/20 0.59
▸ MAOA P21397 1/20 0.58
▸ MAOB P27338 1/20 0.58
▸ CA1 P00915 7/20 0.55
▸ CA2 P00918 7/20 0.55
▸ CA12 O43570 6/20 0.55
▸ CA9 Q16790 6/20 0.55
▸ EPHX1 P07099 2/20 0.44
▸ HTT P42858 1/20 0.43
▸ STK17B O94768 1/20 0.43
▸ STK17A Q9UEE5 1/20 0.43
▸ CYP3A4 P08684 1/20 0.42
▸ DRD2 P14416 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1616400 0.98 TDP1 (0.71) TDP1MEN1GAAKMT2AMAOA
SCHEMBL7527044 0.98 TDP1 (0.71) TDP1MEN1GAAKMT2AMAOA
SCHEMBL29368579 0.98 TDP1 (0.71) TDP1MEN1GAAKMT2AMAOA
SCHEMBL2702906 0.98 TDP1 (0.71) TDP1MEN1GAAKMT2AMAOA
SCHEMBL30167422 0.98 TDP1 (0.71) TDP1MEN1GAAKMT2AMAOA
SCHEMBL2501870 0.94 TDP1 (0.65) TDP1MEN1GAAKMT2AMAOA
SCHEMBL25770347 0.92 TDP1 (0.58) TDP1MEN1GAAKMT2AMAOA
SCHEMBL3020258 0.90 TDP1 (0.81) TDP1MEN1GAAKMT2AMAOA
SCHEMBL25756211 0.88 TDP1 (0.54) TDP1MEN1GAAKMT2AMAOA
SCHEMBL5162656 0.88 TDP1 (0.85) TDP1MEN1GAAKMT2AMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12570804-B2 Supramolecular biomedical polymers SUPRAPOLIX B.V. (NL) 2026-03-10 — — US disclosed
US-12139459-B2 Enhancer of fertilization function of sperm TOHOKU UNIVERSITY (JP) 2024-11-12 — — US disclosed
US-20240110015-A1 SUPRAMOLECULAR BIOMEDICAL POLYMERS SUPRAPOLIX B.V. (NL) 2024-04-04 — — US disclosed
US-11884781-B2 Supramolecular biomedical polymers SUPRAPOLIX B.V. (NL) 2024-01-30 — — US disclosed
EP-4234031-A2 C40-, C28-, AND C-32-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS Revolution Medicines, Inc. (US) 2023-08-30 — — EP disclosed
EP-3713990-B1 SUPRAMOLECULAR BIOMEDICAL POLYMERS SUPRAPOLIX BV (NL) 2023-08-02 — — EP disclosed
CN-111655757-B Supramolecular biomedical polymers 苏普拉普利克斯私人有限公司 2022-10-28 — — CN disclosed
US-20220106270-A1 ENHANCER OF FERTILIZATION FUNCTION OF SPERM KAKE EDUCATIONAL INSTITUTION (JP) 2022-04-07 — — US disclosed
US-11147796-B2 Agent for preventing or ameliorating hearing impairment TOHOKU UNIVERSITY (JP) 2021-10-19 — — US disclosed
US-11147796-B2 Agent for preventing or ameliorating hearing impairment TOHOKU UNIVERSITY (JP) 2021-10-19 — — US disclosed
US-20110213143-A1 COMPOUND HAVING TAFIA INHIBITORY ACTIVITY TAISHO PHARMACEUTICAL CO., LTD. (JP) 2011-09-01 — — US disclosed
EP-2361910-A1 COMPOUND HAVING TAFIA INHIBITORY ACTIVITY Taisho Pharmaceutical Co., Ltd. (JP) 2011-08-31 — — EP disclosed
US-20090181928-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-07-16 — — US disclosed
EP-2038267-A2 THIADIAZOLIDINONE INHIBITORS OF PTPASE Novartis AG (CH) 2009-03-25 — — EP disclosed
WO-2007115058-A2 THIADIAZOLIDINONE INHIBITORS OF PTPASE NOVARTIS AG (CH) 2007-10-11 — — WO disclosed
CN-1859912-A Inhibitors of Akt activity SMITHKLINE BEECHAM CORP (US) 2006-11-08 — — CN disclosed
US-6630488-B1 Quinolizinones as integrin inhibitors BIOCHEM PHARMA, INC. (CA) 2003-10-07 — — US disclosed
CN-1443173-A Substituted imidazoles as TAFI a inhibitors PFIZER LTD (US) 2003-09-17 — — CN disclosed
EP-1115724-A1 QUINOLIZINONES AS INTEGRIN INHIBITORS Shire Biochem Inc. (CA) 2001-07-18 — — EP disclosed
WO-2000017197-A1 QUINOLIZINONES AS INTEGRIN INHIBITORS BIOCHEM PHARMA INC. (US) 2000-03-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12570804-B2 Supramolecular biomedical polymers FGB, BMP1, F2 TDP1 689/4885MEN1 1899/4885GAA 4775/4885
US-20110213143-A1 COMPOUND HAVING TAFIA INHIBITORY ACTIVITY TAF1, TAF5, TAF11 TDP1 1125/4885MEN1 4119/4885GAA 1535/4885
US-12139459-B2 Enhancer of fertilization function of sperm CATSPER1, NASP, ZP1 TDP1 3888/4885MEN1 4153/4885GAA 4111/4885
US-11147796-B2 Agent for preventing or ameliorating hearing impairment SLC26A4, OTC, SLC25A20 TDP1 2836/4885MEN1 1339/4885GAA 3747/4885
US-20090181928-A1 ORGANIC COMPOUNDS PTPRS, PTPRO, PTPRC TDP1 1055/4885MEN1 4439/4885GAA 659/4885
US-20220106270-A1 ENHANCER OF FERTILIZATION FUNCTION OF SPERM CATSPER1, NASP, ZP1 TDP1 3888/4885MEN1 4153/4885GAA 4111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.